These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 23795914)

  • 1. Protein kinase C inhibitors: a patent review (2008 - 2009).
    Sobhia ME; Grewal BK; Ml SP; Patel J; Kaur A; Haokip T; Kokkula A
    Expert Opin Ther Pat; 2013 Oct; 23(10):1297-315. PubMed ID: 23795914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein kinase C inhibitors: a patent review (2010 - present).
    Sobhia ME; Grewal BK; Paul ML; Patel J; Kaur A; Haokip T; Kokkula A
    Expert Opin Ther Pat; 2013 Nov; 23(11):1451-68. PubMed ID: 23795866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical and clinical development of novel agents that target the protein kinase C family.
    Serova M; Ghoul A; Benhadji KA; Cvitkovic E; Faivre S; Calvo F; Lokiec F; Raymond E
    Semin Oncol; 2006 Aug; 33(4):466-78. PubMed ID: 16890801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).
    Gehringer M; Muth F; Koch P; Laufer SA
    Expert Opin Ther Pat; 2015; 25(8):849-72. PubMed ID: 25991433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein kinase C beta inhibitors: a new therapeutic target for diabetic nephropathy and vascular complications.
    Budhiraja S; Singh J
    Fundam Clin Pharmacol; 2008 Jun; 22(3):231-40. PubMed ID: 18485142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a novel class of targeted kinase inhibitors that blocks protein kinase C signaling and ameliorates retinal vascular leakage in a diabetic rat model.
    Grant S; Tran P; Zhang Q; Zou A; Dinh D; Jensen J; Zhou S; Kang X; Zachwieja J; Lippincott J; Liu K; Johnson SL; Scales S; Yin C; Nukui S; Stoner C; Prasanna G; Lafontaine J; Wells P; Li H
    Eur J Pharmacol; 2010 Feb; 627(1-3):16-25. PubMed ID: 19850035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent patents in the discovery of small molecule inhibitors of JAK3.
    Wilson LJ
    Expert Opin Ther Pat; 2010 May; 20(5):609-23. PubMed ID: 20402545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of selective bisubstrate-based inhibitors against protein kinase C (PKC) isozymes by using dynamic peptide microarrays.
    Poot AJ; van Ameijde J; Slijper M; van den Berg A; Hilhorst R; Ruijtenbeek R; Rijkers DT; Liskamp RM
    Chembiochem; 2009 Aug; 10(12):2042-51. PubMed ID: 19618415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Directed modulation of protein kinase C isozyme selectivity with bisubstrate-based inhibitors.
    van Wandelen LT; van Ameijde J; Mady AS; Wammes AE; Bode A; Poot AJ; Ruijtenbeek R; Liskamp RM
    ChemMedChem; 2012 Dec; 7(12):2113-21. PubMed ID: 23139239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PKD at the crossroads of DAG and PKC signaling.
    Wang QJ
    Trends Pharmacol Sci; 2006 Jun; 27(6):317-23. PubMed ID: 16678913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PKC inhibitors: potential in T cell-dependent immune diseases.
    Baier G; Wagner J
    Curr Opin Cell Biol; 2009 Apr; 21(2):262-7. PubMed ID: 19195860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel N-pyrimidin-4-yl-3-amino-pyrrolo [3, 4-C] pyrazole derivatives as PKC kinase inhibitors: a patent evaluation of US2015099743 (A1).
    Das J
    Expert Opin Ther Pat; 2016; 26(4):523-8. PubMed ID: 26593678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Itk inhibitors: a patent review.
    Lo HY
    Expert Opin Ther Pat; 2010 Apr; 20(4):459-69. PubMed ID: 20218931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting protein kinase C subtypes in pancreatic cancer.
    Storz P
    Expert Rev Anticancer Ther; 2015 Apr; 15(4):433-8. PubMed ID: 25604078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein kinase CK2 inhibitors: a patent review.
    Cozza G; Pinna LA; Moro S
    Expert Opin Ther Pat; 2012 Sep; 22(9):1081-97. PubMed ID: 22908959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective PI3Kδ inhibitors, a review of the patent literature.
    Norman P
    Expert Opin Ther Pat; 2011 Nov; 21(11):1773-90. PubMed ID: 22017414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aurora kinase inhibitor patents and agents in clinical testing: an update (2009-10).
    Cheung CH; Coumar MS; Chang JY; Hsieh HP
    Expert Opin Ther Pat; 2011 Jun; 21(6):857-84. PubMed ID: 21591849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
    Dymock BW; See CS
    Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein kinase C intervention: the state of play.
    Roffey J; Rosse C; Linch M; Hibbert A; McDonald NQ; Parker PJ
    Curr Opin Cell Biol; 2009 Apr; 21(2):268-79. PubMed ID: 19233632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p21-Activated kinase inhibitors: a patent review.
    Crawford JJ; Hoeflich KP; Rudolph J
    Expert Opin Ther Pat; 2012 Mar; 22(3):293-310. PubMed ID: 22404134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.